Antitumor Activity of Metformin in Combination with Binimetinib Against Melanoma Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262311403 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Radosław Wolan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jedności 8, 41-200 Sosnowiec,…. Hauptthemen laut MEDLINE: Metformin, Melanoma, Benzimidazoles, Antineoplastic Agents. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia.
Abstract (Originalsprache)
Malignant melanoma is skin cancer with high metastatic potential and resistance to treatment. Significant progress has been made following the introduction of its treatment kinase inhibitors such as binimetinib. Some studies suggested that the combination of metformin with BRAF/MEK inhibitors suppresses cancer cell growth and progression. This study aimed to assess the impact of metformin and binimetinib, both individually and in combination, on the growth, proliferation, and apoptosis of melanoma cells in vitro. The study also sought to predict potential interactions between metformin and binimetinib when co-administered employing in silico analysis. Cell growth and proliferation of melanoma cells exposed to metformin and binimetinib, alone and in combination, were determined by SRB and BRDU assays. Further investigations were performed using real-time RT-qPCR and ELISA method. These results revealed that the simultaneous use of metformin and binimetinib exerted an additive or synergistic inhibitory effect on melanoma cell growth. The concomitant effect of both compounds depended on the concentrations used and was caused by the reduced proliferation and/or increased apoptosis of melanoma cancer cells. In conclusion, the combination of metformin and binimetinib may have potential anticancer effects on melanoma cells; however, more studies are needed to elucidate the exact mechanisms of their combined action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jedności 8, 41-200 Sosnowiec, Poland.
- Department of Pharmacology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jagiellońska 4, 41-200 Sosnowiec, Poland.
- Department of Biopharmacy, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jedności 8, 41-208 Sosnowiec, Poland.
ORCID-Profile: Radosław Wolan, Joanna Wawszczyk, Arkadiusz Orchel, Małgorzata Kapral
Förderung
- Medical University of Silesia
Zitieren
APA
Wolan, R., Wawszczyk, J., Orchel, A., & Kapral, M. (2025). Antitumor Activity of Metformin in Combination with Binimetinib Against Melanoma Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311403
Vancouver
Wolan R, Wawszczyk J, Orchel A, Kapral M. Antitumor Activity of Metformin in Combination with Binimetinib Against Melanoma Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311403
BibTeX
@article{Wolan2025,
author = {Wolan, Radosław and Wawszczyk, Joanna and Orchel, Arkadiusz and Kapral, Małgorzata},
title = {Antitumor Activity of Metformin in Combination with Binimetinib Against Melanoma Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262311403}
}
EUVIMED